BAX vs SOLV: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BAX and SOLV share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BAX and SOLV exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Baxter International makes essential hospital and critical-care products, including IV solutions, infusion pumps (the Novum IQ and legacy platforms), premixed and injectable drugs, surgical sealants, and connected-care hardware from the Hillrom acquisition. After decades as a sprawling healthcare conglomerate, Baxter reshaped itself: it spun off and then sold its Kidney Care segment (rebranded Vantive) to Carlyle for roughly $3.8 billion, using proceeds to reduce debt. What remains is a company centered on Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals, serving hospitals worldwide with high-volume, mission-critical supplies.

Full BAX guide

Solventum is a healthcare company that was spun off from 3M in 2024, combining 3M's former Health Care business into a standalone public company. It operates across several healthcare segments: medical surgical products (wound care, advanced dressings, surgical supplies, infection prevention), dental and orthodontic solutions, health information systems (clinical documentation, coding, and revenue-cycle software for hospitals), and purification and filtration (including water and biopharma filtration). The company makes money selling consumable medical products to hospitals and clinics, software and services to health systems, and filtration technology to industrial and life-science customers. As a recent spin-off, Solventum's story centers on standing up independent operations, paying down debt inherited at separation, stabilizing growth, and improving margins. It holds established brands and large installed bases in several niches. Headquartered in Maplewood, Minnesota, it serves customers across hospital, dental, and industrial end markets globally. Over the twelve months to June 2026, revenue was about $8.3 billion, growing in the low single digits, and the company employed roughly 20,600 people.

Full SOLV guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BAX drivers: Margin and operational turnaround; Deleveraging after the Vantive sale.
• SOLV drivers: Recurring consumable and software revenue; Spin-off self-help and margin expansion.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The Novum LVP pump shipment hold was expected to persist through the year with no committed resolution timeline, pressuring both revenue and profit. For SOLV, as a recent spin-off, Solventum carries meaningful debt taken on at separation (about $5.3 billion against roughly $0.4 billion of cash in mid-2026) and must prove it can grow organically after years inside 3M, where the business reportedly underinvested; revenue grew only about 2% year over year in the June 2026 quarter.

Pick BAX if you believe its drivers more; SOLV if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BAX and SOLV guides.

BAX. Baxter trades at about 12.6 times forward earnings and roughly 1.2 times sales, a modest valuation for medtech that reflects its low-growth profile and the debt load, even after a 31% rally in 2026. Reported GAAP profit is still negative over the trailing year because of special charges, so adjusted metrics and the coming October 29 report (consensus about $0.52 per share) carry most of the weight.

SOLV. Solventum still trades at a discount to faster-growing medtech peers (about 12x forward earnings and under 2x sales in October 2026), a gap explained by slow top-line growth, elevated post-spin debt, and the work still required to prove independent execution. The trailing P/E near 10.5x flatters the picture because GAAP earnings include an unusually large September 2025 quarter. Analysts expect about $7.14 of EPS in 2026 and ~$7.25 in 2027, so successful deleveraging and margin work, more than revenue growth, remain the swing factors.

Headline figures (approximate, October 2026): BAX shows revenue (ttm) ~$11.5B, q2 2026 sales ~$2.96B, up ~5% year over year, q2 2026 adjusted eps ~$0.56 vs ~$0.37 expected, operating margin (ttm) ~14%; SOLV shows revenue (ttm) ~$8.3 billion, revenue growth ~2% year over year in Q2 2026, margins (ttm) gross ~55%, GAAP operating ~10%, q2 2026 adjusted eps $2.55 vs ~$1.91 consensus.

BAX and SOLV are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BAX and SOLV exposure against your real portfolio. It is not an investment adviser.